Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne

摘要

Objective: To characterize minocycline pharmacokinetics and relative bioavailability following multiple-dose topical administration of minocycline hydrochloride (HCI) foam 4% (FMX101 4%) as compared with single-dose oral administration of minocycline HCI extended-release tablets (Solodyn (R)) in subjects with moderate-to-severe acne.